Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Cytokinetics Partners with Sanofi To Develop Aficamten in Greater China
Details : Sanofi will acquire CORXEL’s rights relating to CK-3773274 (aficamten) in Greater China> It is being evaluated for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 20, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Edaravone,Dexborneol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanbexin Sublingual Tablets Receive Breakthrough Therapy Designation from FDA
Details : Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.
Product Name : Sanbexin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : Edaravone,Dexborneol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edaravone,Dexborneol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : NeuroDerm
Deal Size : Inapplicable
Deal Type : Inapplicable
Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA
Details : Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.
Product Name : Sanbexin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2024
Lead Product(s) : Edaravone,Dexborneol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : NeuroDerm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : $162.0 million
Deal Type : Series D Financing
Bayer and RTW Investments Lead Series D in Chinese Biotech Ji Xing Pharmaceuticals
Details : The financing will enable the company to support Ji Xing Pharmaceuticals in the commercialization of JIXING’s pipeline assets in the areas of cardiovascular diseases and ophthalmology.
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 06, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : $162.0 million
Deal Type : Series D Financing
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MYK-461 (mavacamten) is a cardiac myosin inhibitor approved by the U.S. FDA indicated for the treatment of adults with symptomatic new york heart association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms.
Product Name : MYK-461
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2023
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MYK-461 (Mavacamten) is a cardiac myosin inhibitor approved by the U.S. FDA indicated for the treatment of adults with symptomatic new york heart association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms.
Product Name : MYK-461
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2023
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ongericimab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JS002 (ongericimab) is a recombinant humanized anti-PCSK9 monoclonal antibody independently, being developed for the treatment of primary hypercholesterolemia and mixed hyperlipedemia.
Product Name : JS002
Product Type : Antibody
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : Ongericimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ebronucimab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : AD Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
NMPA Accepted Akeso's Ebronucimab (PCSK9) Marketing Application in two Cardiovascular Indications
Details : NMPA has accepted its NDA for its fully human anti-PCSK9 monoclonal antibody AK102 (ebronucimab) for 2 indications 1) primary hypercholesterolemia and mixed hyperlipidemia, and 2) heterozygous familial hypercholesterolemia.
Product Name : AK102
Product Type : Antibody
Upfront Cash : Inapplicable
January 06, 2023
Lead Product(s) : Ebronucimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : AD Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MYK-461 (mavacamten) is the first and only cardiac myosin inhibitor approved by the U.S. FDA indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms...
Product Name : MYK-461
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 08, 2022
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : MyoKardia
Deal Size : Inapplicable
Deal Type : Inapplicable
LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers
Details : MYK-461 (mavacamten) is the first and only cardiac myosin inhibitor, that demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers.
Product Name : MYK-461
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2022
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : MyoKardia
Deal Size : Inapplicable
Deal Type : Inapplicable